Activation of Vasopressin System During COVID-19 is Associated With Adverse Clinical Outcomes: An Observational Study.
Claudia GregorianoAlexandra MolitorEllen HaagAlexander KutzDaniel KochSebastian HaubitzAnna ConenLuca BernasconiAngelika Hammerer-LercherChristoph A FuxBeat MuellerPhilipp SchuetzPublished in: Journal of the Endocrine Society (2021)
A pronounced activation of the vasopressin system in COVID-19 patients is associated with an adverse clinical course in COVID-19 patients. This finding, however, is not unique to COVID-19 but similar to other types of respiratory infections.
Keyphrases